Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial

Yu-Tao Liu,1 Xue-Zhi Hao,1 De-Ruo Liu,2 Gang Cheng,3 Shu-Cai Zhang,4 Wen-Hua Xiao,5 Yi Hu,6 Jun-Feng Liu,7 Ming He,7 Cui-Min Ding,8 Li Zhang,9 Jun Wang,10 Hui Li,11 Gui-Lan Dong,12 Xiu-Yi Zhi,13 Jian Li,14 Yuan-Kai Shi1 1Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Ant...

Full description

Bibliographic Details
Main Authors:	Liu YT, Hao XZ, Liu DR, Cheng G, Zhang SC, Xiao WH, Hu Y, Liu JF, He M, Ding CM, Zhang L, Wang J, Li H, Dong GL, Zhi XY, Li J, Shi YK
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-06-01
Series:	Cancer Management and Research
Subjects:	efgr mutation non-small-cell lung cancer (nsclc) lung adenocarcinoma icotinib adjuvant chemotherapy
Online Access:	https://www.dovepress.com/icotinib-as-adjuvant-treatment-for-stage-ii-iiia-lung-adenocarcinoma-p-peer-reviewed-article-CMAR

Similar Items

Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trialResearch in context
by: Wei Ou, et al.
Published: (2023-03-01)

Clinical Analysis of Icotinib on Beneficiary of  Advanced Non-small Cell Lung Cancer with EGFR Common Mutation
by: Xiaowen JIANG, et al.
Published: (2016-04-01)

Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride
by: Jingying NONG, et al.
Published: (2013-05-01)

Comparison of the Efficacy and Safety of Icotinib with Standard Second-line  Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer
by: Shuyang YAO, et al.
Published: (2015-06-01)

Prognostic Factors in Patients with Advanced Lung Adenocarcinoma Treated with Icotinib
by: ZHANG Hongbin, et al.
Published: (2022-11-01)

Clinical Observation of Icotinib Hydrochloride in First-line Therapy  for Pulmonary Adenocarcinoma
by: Xinjie YANG, et al.
Published: (2013-07-01)

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
by: Tianze Liu, et al.
Published: (2019-04-01)

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study
by: Zhansheng Jiang, et al.
Published: (2021-09-01)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
by: Wang L, et al.
Published: (2021-03-01)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
by: Xiaojie Chen, et al.
Published: (2022-11-01)

Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib
by: Xin Lyu, et al.
Published: (2022-06-01)

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation
by: Jianxin Chen, et al.
Published: (2022-07-01)

Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR
by: Faisal A. Almalki, et al.
Published: (2021-10-01)

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
by: Linlin Zhang, et al.
Published: (2023-08-01)

Inhibition of miR-22 enhanced the efficacy of icotinib plus pemetrexed in a rat model of non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2020-03-01)

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
by: Chun-Yao Huang, et al.
Published: (2023-05-01)

Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
by: Jie Wang, MD, PhD, et al.
Published: (2024-02-01)

LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma
by: Jie Wu, et al.
Published: (2021-01-01)

Efficacy of icotinib in advanced lung squamous cell carcinoma
by: Shuai Liang, et al.
Published: (2018-09-01)

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism
by: Qi Zhou, et al.
Published: (2023-12-01)

Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells
by: Guohai Wang, et al.
Published: (2019-08-01)

Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer
by: Huawei LIN, et al.
Published: (2020-10-01)

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion
by: Lanzi Ou, et al.
Published: (2022-07-01)

Rapid vision improvement by using icotinib in a patient with bilateral choroidal metastases symmetrically from lung cancer
by: Chaoran Li, et al.
Published: (2023-07-01)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
by: Zhu L, et al.
Published: (2020-11-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
by: Junhui Wang, et al.
Published: (2019-02-01)

Case report: Efficacy of icotinib treatment in lung adenocarcinoma with esophageal squamous cell carcinoma: a rare case of double primary malignant tumors
by: Min Deng, et al.
Published: (2024-03-01)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
by: Zhang SS, et al.
Published: (2022-04-01)

A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion
by: Xiaohong Xie, et al.
Published: (2020-06-01)

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports
by: Yamin Meng, et al.
Published: (2023-09-01)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
by: Long-fei Mao, et al.
Published: (2020-09-01)

Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study
by: Qian J, et al.
Published: (2020-05-01)

Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1
by: Xuewei Cheng, et al.
Published: (2017-11-01)

Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
by: Emily ePadfield, et al.
Published: (2015-01-01)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
by: Ping Chen, et al.
Published: (2022-09-01)

Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials
by: Pengfei Zhao, et al.
Published: (2022-03-01)

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
by: Jun-Feng Liu, et al.
Published: (2023-03-01)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
by: Hisashi Tanaka, et al.
Published: (2020-06-01)

<i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
by: Xavier Cansouline, et al.
Published: (2022-04-01)